Brief: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
14/01/2025 14:06
Jan 14 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O :
* ACADIA PHARMACEUTICALS SUBMITS MARKETING AUTHORIZATION
APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR TROFINETIDE FOR
THE TREATMENT OF RETT SYNDROME
Source text: ID:nBw6H1jsra
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry